Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects

Emily J. Blake, Paul M. Norris, Sally Faith Dorfman, James Longstreth, Vladimir I. Yankov

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To determine pharmacokinetic profiles of two times a day and three times a day dosage regimens of Endometrin, a micronized progesterone vaginal insert for luteal support in assisted reproductive technology, compared with a gel. Design: A single-center, randomized, open-label, single-day, and multiple-day (5 days) parallel design pharmacokinetic study. Setting: University clinical research unit. Patient(s): Three groups of six healthy subjects, ages 18 to 40 years. Intervention(s): Endometrin vaginal inserts two times a day or three times a day, or gel daily. Main Outcome Measure(s): Pharmacokinetic profiles. Result(s): Progesterone serum concentrations increased rapidly following administration of Endometrin vaginal insert, producing higher peak concentrations (Cmax) and clearing faster than gel. On the single day of dosing, mean Cmax was 17.0 ± 2.7 ng/mL in the two times a day group, 19.8 ± 2.9 ng/mL in the three times a day group, and 6.82 ± 1.69 ng/mL in the gel group. Endometrin treatments reached steady state within the first 2 days (24-36 hours), much more rapidly than the gel, which had not reached steady state by 5 days. At 5 days, the Endometrin treatments produced sustained progesterone concentrations exceeding 10 mg/mL across 24 hours. Conclusions: Endometrin vaginal inserts reached higher Cmax, produced greater systemic exposure (area under the curve 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than the comparator.

Original languageEnglish
Pages (from-to)1296-1301
Number of pages6
JournalFertility and Sterility
Volume94
Issue number4
DOIs
StatePublished - Sep 1 2010

Fingerprint

Foams and Jellies Vaginal Creams
Progesterone
Pharmacokinetics
Gels
Intravaginal Administration
Assisted Reproductive Techniques
Corpus Luteum
Area Under Curve
Healthy Volunteers
Therapeutics
Outcome Assessment (Health Care)
Serum
Research

Keywords

  • assisted reproductive technology
  • Endometrin
  • in vitro fertilization
  • IVF
  • luteal support
  • pharmacokinetics
  • PK
  • progesterone
  • progesterone supplementation
  • vaginal

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. / Blake, Emily J.; Norris, Paul M.; Dorfman, Sally Faith; Longstreth, James; Yankov, Vladimir I.

In: Fertility and Sterility, Vol. 94, No. 4, 01.09.2010, p. 1296-1301.

Research output: Contribution to journalArticle

Blake, Emily J. ; Norris, Paul M. ; Dorfman, Sally Faith ; Longstreth, James ; Yankov, Vladimir I. / Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. In: Fertility and Sterility. 2010 ; Vol. 94, No. 4. pp. 1296-1301.
@article{edfeadde0152436d9b8a427b87c65d2b,
title = "Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects",
abstract = "Objective: To determine pharmacokinetic profiles of two times a day and three times a day dosage regimens of Endometrin, a micronized progesterone vaginal insert for luteal support in assisted reproductive technology, compared with a gel. Design: A single-center, randomized, open-label, single-day, and multiple-day (5 days) parallel design pharmacokinetic study. Setting: University clinical research unit. Patient(s): Three groups of six healthy subjects, ages 18 to 40 years. Intervention(s): Endometrin vaginal inserts two times a day or three times a day, or gel daily. Main Outcome Measure(s): Pharmacokinetic profiles. Result(s): Progesterone serum concentrations increased rapidly following administration of Endometrin vaginal insert, producing higher peak concentrations (Cmax) and clearing faster than gel. On the single day of dosing, mean Cmax was 17.0 ± 2.7 ng/mL in the two times a day group, 19.8 ± 2.9 ng/mL in the three times a day group, and 6.82 ± 1.69 ng/mL in the gel group. Endometrin treatments reached steady state within the first 2 days (24-36 hours), much more rapidly than the gel, which had not reached steady state by 5 days. At 5 days, the Endometrin treatments produced sustained progesterone concentrations exceeding 10 mg/mL across 24 hours. Conclusions: Endometrin vaginal inserts reached higher Cmax, produced greater systemic exposure (area under the curve 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than the comparator.",
keywords = "assisted reproductive technology, Endometrin, in vitro fertilization, IVF, luteal support, pharmacokinetics, PK, progesterone, progesterone supplementation, vaginal",
author = "Blake, {Emily J.} and Norris, {Paul M.} and Dorfman, {Sally Faith} and James Longstreth and Yankov, {Vladimir I.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.fertnstert.2009.06.014",
language = "English",
volume = "94",
pages = "1296--1301",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects

AU - Blake, Emily J.

AU - Norris, Paul M.

AU - Dorfman, Sally Faith

AU - Longstreth, James

AU - Yankov, Vladimir I.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: To determine pharmacokinetic profiles of two times a day and three times a day dosage regimens of Endometrin, a micronized progesterone vaginal insert for luteal support in assisted reproductive technology, compared with a gel. Design: A single-center, randomized, open-label, single-day, and multiple-day (5 days) parallel design pharmacokinetic study. Setting: University clinical research unit. Patient(s): Three groups of six healthy subjects, ages 18 to 40 years. Intervention(s): Endometrin vaginal inserts two times a day or three times a day, or gel daily. Main Outcome Measure(s): Pharmacokinetic profiles. Result(s): Progesterone serum concentrations increased rapidly following administration of Endometrin vaginal insert, producing higher peak concentrations (Cmax) and clearing faster than gel. On the single day of dosing, mean Cmax was 17.0 ± 2.7 ng/mL in the two times a day group, 19.8 ± 2.9 ng/mL in the three times a day group, and 6.82 ± 1.69 ng/mL in the gel group. Endometrin treatments reached steady state within the first 2 days (24-36 hours), much more rapidly than the gel, which had not reached steady state by 5 days. At 5 days, the Endometrin treatments produced sustained progesterone concentrations exceeding 10 mg/mL across 24 hours. Conclusions: Endometrin vaginal inserts reached higher Cmax, produced greater systemic exposure (area under the curve 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than the comparator.

AB - Objective: To determine pharmacokinetic profiles of two times a day and three times a day dosage regimens of Endometrin, a micronized progesterone vaginal insert for luteal support in assisted reproductive technology, compared with a gel. Design: A single-center, randomized, open-label, single-day, and multiple-day (5 days) parallel design pharmacokinetic study. Setting: University clinical research unit. Patient(s): Three groups of six healthy subjects, ages 18 to 40 years. Intervention(s): Endometrin vaginal inserts two times a day or three times a day, or gel daily. Main Outcome Measure(s): Pharmacokinetic profiles. Result(s): Progesterone serum concentrations increased rapidly following administration of Endometrin vaginal insert, producing higher peak concentrations (Cmax) and clearing faster than gel. On the single day of dosing, mean Cmax was 17.0 ± 2.7 ng/mL in the two times a day group, 19.8 ± 2.9 ng/mL in the three times a day group, and 6.82 ± 1.69 ng/mL in the gel group. Endometrin treatments reached steady state within the first 2 days (24-36 hours), much more rapidly than the gel, which had not reached steady state by 5 days. At 5 days, the Endometrin treatments produced sustained progesterone concentrations exceeding 10 mg/mL across 24 hours. Conclusions: Endometrin vaginal inserts reached higher Cmax, produced greater systemic exposure (area under the curve 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than the comparator.

KW - assisted reproductive technology

KW - Endometrin

KW - in vitro fertilization

KW - IVF

KW - luteal support

KW - pharmacokinetics

KW - PK

KW - progesterone

KW - progesterone supplementation

KW - vaginal

UR - http://www.scopus.com/inward/record.url?scp=77956188164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956188164&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2009.06.014

DO - 10.1016/j.fertnstert.2009.06.014

M3 - Article

C2 - 19608168

AN - SCOPUS:77956188164

VL - 94

SP - 1296

EP - 1301

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -